OVARIAN CANCER

I. Overview

With the aging of the global trend of development, improve the economic status of women, more and more women start hormone replacement therapy (Hormone Replacement Therapy, HRT), to improve access to after menopause due to the decrease in the level of sex hormones related to various diseases. Clear evidence that: postmenopausal women with age, the incidence of coronary heart disease increased by about four times the fracture due to osteoporosis by 20%, died of complications due to pelvic fracture rate of 30%, after the 65-year-old Alzheimer's incidence rate increase every year <BR> and Application HRT can peer groups coronary heart disease risk 50% Alzheimer's risk reduced three times, especially worth mentioning is significantly reduced the incidence of rectal cancer. Long-term use of HRT cancer risk reduced year by year. HRT can also greatly improve the menopause, postmenopausal women with disease or ovarian surgery, radiotherapy in patients with a series of artificial menopause syndrome.

Tags: age, benign, blood, body, brca1, breast, cancer, carcinoma, care, cases, cause, cell, cells, clinical, cyst, cystic, diagnosis, diet, drug, early, eat, ert, estrogen, family, fat, gene, grams, group, groups, growth, gynecological, history, hrt, incidence, increased, injection, intravenous, life, lymph, malignant, metastasis, method, mutation, node, ovarian, patients, pelvic, positive, protein, quality, radiotherapy, rate, reduce, residual, risk, screening, second, study, surgery, surgical, survival, syndrome, therapy, time, treatment, tumor, tumors, usually, uterine, women

Cytoreductive surgery in the treatment of ovarian cancer Comprehensive Application and prospects

Foreign Medical Obstetrics and Gynecology volumes in 1999 Vol 26 No. 2

Tianjin Medical University General Hospital of Obstetrics and Gynecology (300,052) of the new QU (Summary) if Mi (revision)

Abstract <BR> since the 1980s, complete cytoreductive surgery to cisplatin-based combination chemotherapy for ovarian cancer as a conventional model, cytoreductive surgery is the complete impact of the prognosis of patients with one of the important factors for recurrent ovarian cancer once again cytoreductive surgery still some value , but to improve the survival rate of patients is more important to be effective after chemotherapy treatment as a necessary complement. Early ovarian cancer retroperitoneal lymph node dissection is reasonable and significance of the still controversial.

Tags: abdominal, age, annex, anti, bleeding, blood, cancer, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, diagnosis, drug, drugs, early, eat, ert, exploration, gene, growth, incidence, increased, intraperitoneal, intravenous, life, lymph, malignant, metastasis, metastatic, method, mutation, node, ovarian, p53, patients, pelvic, physical, poor, positive, prognosis, quality, rate, reduce, resection, residual, response, second, staging, study, surgery, surgical, survival, therapy, time, toxicity, treatment, tumor, tumors

Mesenchymal cells of the ovary (Loydig cell tumor):

(1) of the cell door: This tumor is rare. As a <BR> ovarian portal that since the tumor cell door. More common in women after menopause, the main clinical manifestations of masculine symptoms, but sometimes there will be high performance estrogen, and with endometrial hyperplasia, endometrial cancer.

[Giant seizure] often unilateral, bilateral and occasionally simultaneously ovarian tumor. Tumor sizes. In ovarian portal, but the majority of ovarian tumors can be occupied. Tumor section for substantive, yellow or brownish yellow, with cystic degeneration and bleeding.

Tags: anti, bleeding, cancer, cell, cells, clinical, cyst, cystic, estrogen, gene, ovarian, ovary, symptoms, time, tumor, tumors, women

Ovarian cancer

Tags: abdominal, age, body, cancer, cause, cell, cells, chemotherapy, clinical, days, early, eat, ert, examination, family, gene, grams, gynecological, life, ovarian, patients, pelvic, poor, quality, radiotherapy, surgery, surgical, survival, symptoms, therapy, treatment, tumor, women

The rapid growth of ovarian cancer, easy-proliferation. But often asymptomatic patients in the early, often in gynecological examination discovered accidentally, or that tumor growth beyond a certain size pelvic, abdominal be palpable timely, or when complications are found, up until the time of medical treatment are often already late. The symptoms of ovarian cancer may be due to tumor size, timing, whether complications vary. Common symptoms are:

(1) Occasionally the early side of the infrarenal abdominal discomfort or pain with sinkers flu.

Tags: abdominal, bleeding, blood, cancer, cause, clinical, early, eat, ert, examination, growth, gynecological, life, mass, oppression, ovarian, pain, patients, pelvic, physical, quality, symptoms, time, treatment, tumor, tumors

Abstract: a group P53 mutations in the genes in patients with advanced ovarian cancer by more cycles of P53 gene therapy and chemotherapy, reducing disease, the survival rate has improved. (The Fourth Annual Gene Therapy & Molecular Biology Conference, Rhodes, Greece)

American University of Iowa Dr. Richard Buller reported they received early treatment to strengthen the 36 patients with advanced ovarian cancer to the adenovirus vector into the peritoneal tumor suppressor gene p53 function of the combination of chemotherapy I / II clinical trials of the preliminary results. The results show that several gene therapy / chemotherapy combination therapy in patients with an average survival of 14.8. Nine people have survived 19.5 months, are still alive. The survival rate is higher than five separate gene therapy on the survival rate is also higher than the average with paclitaxel (Taxol) in the treatment of recurrent ovarian cancer new 15-month survival rate.

Tags: age, cancer, carboplatin, cause, chemotherapy, clinical, early, eat, gene, group, intraperitoneal, mutation, ovarian, p53, paclitaxel, patients, rate, reduce, survival, taxol, therapy, treatment, tumor

Ovarian cancer mortality first Habitat gynecologic malignancies, as misprision of onset, 70% of patients when treatment is already advanced. Surgery and chemotherapy comprehensive application is the treatment of advanced ovarian cancer, especially epithelial ovarian cancer therapy of choice. Platinum drug resistance ovarian cancer is the main reason for treatment failure. To solve this problem, clinical oncologist to a variety of solutions, is chosen in 2003 after the open literature on the following:

Tags: anti, cancer, carboplatin, cases, cell, cells, chemotherapy, cisplatin, clinical, csa, days, dose, drug, drugs, eat, head, injection, intravenous, method, ovarian, paclitaxel, patients, positive, rate, reduce, response, study, surgery, survival, therapy, time, toxicity, treatment

[Summary]

Ovarian cancer is a common cancer of female genital mutilation one of the incidence of cervical cancer and after cancer of the uterus, which ranked third. But ovarian cancer death, accounts of the first gynecologic tumors, right pose a serious threat to women's lives. Because ovarian embryonic development, organization anatomy and endocrine function more complicated, it may be suffering from benign tumors or malignant. Because of early ovarian cancer in asymptomatic, and the identification of its type benign and malignant very difficult, ovarian carcinoma laparotomy in ovarian tumor confined to only 30%, most have spread to the uterus, bilateral annex, the omentum and pelvic organs, both in the diagnosis of ovarian cancer and governance the treatment is a major problem indeed. Over the years experts on the pathological form of ovarian cancer, the development of clinical and treatment programs for many of accumulated a lot of experience, so far, statistics on domestic and foreign clinical data, the five-year survival rate of only 25% to 30%.

Tags: abdominal, age, amenorrhea, annex, anti, benign, bleeding, blood, body, cancer, carcinoma, care, cases, cause, cell, cells, chemotherapy, clinical, cyst, cystic, days, diagnosis, dose, drug, drugs, early, eat, ert, estrogen, examination, exploration, gene, grams, growth, gynecological, history, incidence, increased, injection, intraperitoneal, intravenous, irradiation, life, lymph, malignant, mass, metastasis, method, node, oppression, ovarian, ovary, pain, patients, pelvic, poor, prognosis, protein, radiation, radiotherapy, rate, reduce, resection, residual, screening, staging, surface, surgery, surgical, survival, symptoms, syndrome, therapy, time, toxicity, treatment, tumor, tumors, uterine, women

Ovarian cancer
	Ovarian cancer is a malignancy in ovarian tissue. Clinically, there will be abdominal discomfort, abdominal pain, abdominal mass, menstrual disorders, oppression and other symptoms. Ovarian cancer onset conceal, not found early, easy transfer characteristics of poor prognosis. Of all gynecologic malignancies around 15%. The incidence of ovarian cancer in common malignancy in women as a percentage of 2.4-5.6%. In the female reproductive tract malignancies in the third place, behind cervical and uterine corpus cancer. In women's reproductive tract cancers, ovarian cancer is the highest cause of death of a tumor. Ovarian cancer can occur at any age. Ovarian cancer belong to the medicine "of Zheng Jia", "build up" areas.

Tags: abdominal, age, body, cancer, cause, cell, cells, clinical, early, eat, incidence, mass, oppression, ovarian, pain, poor, prognosis, symptoms, tumor, uterine, women

Common and prognosis factors:

• clinical stage and is closely related to survival;

• histological type and grade pathology and prognosis is directly related;

• differentiation and biological characteristics and the prognosis also directly related to a direct impact on the survival rate and survival time.

• In addition, the age factor and the prognosis of more closely. Another treatment option with a reasonable and thorough, but also directly affect the prognosis of ovarian cancer.

Tags: age, body, cancer, chemotherapy, clinical, eat, exploration, life, method, ovarian, patients, prognosis, rate, residual, surgery, survival, therapy, time, treatment, tumor